Keywords: amylin, loss, 4th-qtr, worsens, higher, marketing, costs
Amylin's loss for 4th-qtr 2007 worsens 32%
Article | 04 February 2008
Higher marketing costs associated with the diabetes drugs Byetta (exenatide) and Symlin (pramlintide acetate), led to increased fourth-quarter 2007 losses at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
